Antibody that binds to CD3 epsilon

Abstract

To provide methods and compositions relating to variant nucleic acid libraries encoding for antibodies including single domain antibodies.SOLUTION: Libraries generated using methods described herein have improved characteristics including improved binding affinity. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.SELECTED DRAWING: Figure 29D

Claims

1. An antibody or antigen-binding fragment that binds to CD3 epsilon, wherein the antibody or antigen-binding fragment comprises CDRH1, CDRH2, and CDRH3 on the variable region of the heavy chain (VH) and CDRL1, CDRL2, and CDRL3 on the variable region of the light chain (VL), Here, the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 are, (a) Sequence numbers 118, 121, 124, 129, 132 and 135, respectively (b) Sequence numbers 119, 122, 125, 130, 133 and 136, respectively, (c) Sequence IDs 120, 123, 126, 131, 134 and 137, respectively An antibody or its antigen-binding fragment containing the amino acid sequence described in [the relevant document].

2. The antibody or antigen-binding fragment according to claim 1, wherein the VH comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence described in SEQ ID NO: 138 or 140.

3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the VH comprises the amino acid sequence described in SEQ ID NO: 138 or 140.

4. The antibody or antigen-binding fragment according to any one of claims 1 to 3, wherein the VL comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence described in SEQ ID NO: 142 or 144.

5. The antibody or antigen-binding fragment according to any one of claims 1, 2, or 4, wherein the VL comprises the amino acid sequence described in SEQ ID NO: 142 or 144.

6. An antibody or antigen-binding fragment that binds to CD3 epsilon, wherein the antibody or antigen-binding fragment comprises a variable region of a heavy chain (VH) and a variable region of a light chain (VL), wherein the VH comprises the amino acid sequence described in SEQ ID NO: 138 and the VL comprises the amino acid sequence described in SEQ ID NO:

142.

7. An antibody or antigen-binding fragment that binds to CD3 epsilon, wherein the antibody or antigen-binding fragment comprises a variable region of a heavy chain (VH) and a variable region of a light chain (VL), wherein the VH comprises the amino acid sequence described in SEQ ID NO: 140 and the VL comprises the amino acid sequence described in SEQ ID NO:

144.

8. An antibody or antigen-binding fragment that binds to CD3 epsilon, wherein the antibody or antigen-binding fragment comprises a variable region of a heavy chain (VH) containing the amino acid sequence described in SEQ ID NO: 139, and a variable region of a light chain (VL) containing the amino acid sequence described in SEQ ID NO:

143.

9. An antibody or antigen-binding fragment that binds to CD3 epsilon, wherein the antibody or antigen-binding fragment comprises a variable region of a heavy chain (VH) containing the amino acid sequence described in SEQ ID NO: 141, and a variable region of a light chain (VL) containing the amino acid sequence described in SEQ ID NO:

145.

10. An isolated nucleic acid comprising a sequence encoding the antibody or its antigen-binding fragment according to any one of claims 1 to 9.

11. An expression vector comprising the isolated nucleic acid described in claim 10.

12. Isolated cells comprising the isolated nucleic acid according to claim 10 or the expression vector according to claim 11.

Images